garcinone E: has potent cytotoxic effect against hepatocellular carcinoma cell lines; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10298511 |
| CHEMBL ID | 454580 |
| CHEBI ID | 185712 |
| SCHEMBL ID | 4755998 |
| MeSH ID | M0444930 |
| Synonym |
|---|
| REGID_FOR_CID_10298511 |
| MEGXP0_001391 |
| ACON1_001486 |
| NCGC00180455-01 |
| smr000440775 |
| MLS000863599 |
| ACON0_000339 |
| 2,3,6,8-tetrahydroxy-1,4,7-tris(3-methylbut-2-enyl)xanthen-9-one |
| bdbm50242205 |
| cid_10298511 |
| BRD-K71193328-001-01-5 |
| CHEMBL454580 , |
| 112649-21-5 |
| garcinone e |
| CHEBI:185712 |
| HMS2269C06 |
| SCHEMBL4755998 |
| 2,3,6,8-tetrahydroxy-1,4,7-tris(3-methylbut-2-en-1-yl)-9h-xanthen-9-one |
| 7-o-demethyl-5-prenyl-alpha-mangostin |
| unii-83jja5l4zg |
| 83JJA5L4ZG , |
| 7-o-demethyl-5-prenyl-.alpha.-mangostin |
| 1,4,7-tris(3-methylbut-2-enyl)-2,3,6,8-tetrakis(oxidanyl)xanthen-9-one |
| 9h-xanthen-9-one, 2,3,6,8-tetrahydroxy-1,4,7-tris(3-methyl-2-buten-1-yl)- |
| DTXSID001318292 |
| HY-123901 |
| CS-0086788 |
| AKOS040761773 |
| FS-7912 |
| Class | Description |
|---|---|
| xanthones | Any member of the class of xanthenes based on a xanthone skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 22.3872 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 14.1254 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.7407 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 50.1187 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 32.6294 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 19.4763 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.3872 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 6.3096 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 28.1838 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| PINK1 | Homo sapiens (human) | Potency | 8.9125 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 19.9526 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 25.2855 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| Parkin | Homo sapiens (human) | Potency | 8.9125 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 50.1187 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| IDH1 | Homo sapiens (human) | Potency | 16.3601 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 25.9290 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 31.6228 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 19.3736 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 44.6684 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| snurportin-1 | Homo sapiens (human) | Potency | 19.3736 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 50.1187 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 16.3601 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 12.5893 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 27.7170 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 25.9290 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 56.2341 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 3.9811 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 19.3512 | 1.9953 | 25.5327 | 50.1187 | AID624287; AID624288 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| XBP1 | Homo sapiens (human) | IC50 (µMol) | 5.2400 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
| tumor necrosis factor | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0793 | 5.8098 | 14.7275 | AID2485 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 9.6700 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
| nucleotide-binding oligomerization domain-containing protein 2 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 4.6490 | 1.1460 | 7.1372 | 19.7000 | AID2001 |
| Aromatase | Homo sapiens (human) | IC50 (µMol) | 25.1000 | 0.0000 | 1.2904 | 10.0000 | AID343720 |
| Fatty acid synthase | Homo sapiens (human) | IC50 (µMol) | 3.3000 | 0.0077 | 2.4624 | 5.8000 | AID517164 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nucleotide-binding oligomerization domain-containing protein 1 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 4.7800 | 0.1700 | 7.2584 | 18.7000 | AID1578 |
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.8280 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID343718 | Inhibition of aromatase in human placental microsomes at 20 ug/ml relative to control | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. |
| AID343723 | Cytotoxicity against human SKBR3 cells assessed as survival by MTT assay relative to control | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. |
| AID421810 | Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthin incorporation after 24 to 72 hrs | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Cytotoxic and antiplasmodial xanthones from Pentadesma butyracea. |
| AID421809 | Antiplasmodial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcB1 by [3H]hypoxanthine uptake | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Cytotoxic and antiplasmodial xanthones from Pentadesma butyracea. |
| AID421811 | Ratio IC50 for human MCF7 cells to IC50 for chloroquine-resistant Plasmodium falciparum FcB1 | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Cytotoxic and antiplasmodial xanthones from Pentadesma butyracea. |
| AID343720 | Inhibition of aromatase in human placental microsomes | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. |
| AID517164 | Inhibition of FAS | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana. |
| AID356334 | Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by Trypan blue exclusion test | 2003 | Journal of natural products, Aug, Volume: 66, Issue:8 | Induction of apoptosis by xanthones from mangosteen in human leukemia cell lines. |
| AID343721 | Inhibition of aromatase over-expressed in human SKBR3 cells at 50 uM relative to control | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | |||
| AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | |||
| AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | |||
| AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 6 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||